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Abstract: Oral Lichen Planus (OLP) is a chronic inflammatory condition implicating T cell-mediated cytotoxicity, and involving oral 
mucosal surfaces. Several therapeutic regimens have been evaluated to treat OLP and pain related, but often without high level of evi-
dence. Topical formulations are the favourite for the majority of cases; bioadhesive formulations have been considered very useful and 
practical for local drug delivery in oral mucosa, due to the increased residence time on the oral mucosa of the dosage forms and better 
therapeutic efficacy.  
In this narrative review, authors try to illustrate the current topical managements for OLP from the accessible literature on this topic. 
Steroids are very helpful in discomfort and making better quality of life: they are considered the first-line treatment even if they could 
cause secondary candidosis, and sometimes bad taste, nausea, dry mouth, sore throat or swollen mouth. 
Other substances or devices by topical administration are adopted especially when the first line approach is refractory. This is the case 
when retinol with its synthetic and natural analogues (retinoids), hyaluronic acid, or Aloe Vera are chosen.  
Recent topical applications for OLP therapy include phototherapy and low/high energy pulsing light; the treatment with extracorporeal 
photochemotherapy is also reasonable and promising. 
Finally, calcineurin inhibitors (i.e. cyclosporine, tacrolimus and pimecrolimus), antioxidant and biologics (i.e alefacept, efalizumab, 
basiliximab, TNF- inhibitors - infliximab, rituximab) may be alternative approaches when OLP does not respond to the standard proto-
cols. 
In this scenario, there are several studies on molecules different from glucocorticosteroids, but not sufficient or statistically adequate to 
justify their evidence-based use in OLP; large randomized placebo controlled trials are required to evaluate the safety and effectiveness of 
these non conventional therapies.  
In conclusion, since OLP is a chronic disease and requires long-term management, the dental/medical practitioner, who treats OLP pa-
tients, needs to know the natural history of OLP, how to monitor, and how to treat, taking in account all of the available modalities con-
ventional and not, with pros and cons.  
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INTRODUCTION 
 Lichen planus (LP) is an inflammatory mucocutaneous condi-
tion involving T cell-mediated cytotoxicity for reasons not yet de-
finitively clarified. It affects skin and mucous membranes of strati-
fied squamous epithelium with different clinical features [1, 2]. 
 Sometimes, LP could be present in concomitant areas, with the 
epithelium being common to the other anatomic sites: oral, genital, 
nasal mucosa, and nails, rarely conjunctiva, larynx, and esophagus 
[3-5]. It has been also described a lichen planopilaris that involves 
the hair follicles resulting in scarring alopecia [6]. 
 Oral mucosal lesions occur in 50 to 70% of the patients with 
LP. Oral lichen planus (OLP) affects 2% of the population with the 
highest incidence in women (2: 1), and the most affected age ranges 
from 40-70 years [7-22].  
 Current practice for the treatment of OLP (Table 1) seeks to 
ameliorate the symptoms and discomfort, to improve the normal 
functions (i.e. eating and speaking) and quality of life. In general, 
reticular and plaque forms do not necessitate a therapy, but only 
symptomatic forms need to be treated, and management is aimed to  
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monitor the lesions and to reduce the frequency and seriousness of 
acute forms (Figs. 1, 2). Firstly, the elimination of irritating factors 
(e.g. maloccluded/fractured teeth, scarce oral hygiene, voluptuary 
habits) should be counselled.  
 Evaluation of effectiveness in OLP treatment strategy is com-
plicated by many factors: patient’s psychological profile and medi-
cal/pharmacological history (e.g. side effects, interactions) as well 
as compliance to maintain a good oral health. This latter aspect 
becomes fundamental if the OLP is solely or also localised on the 
gingival surfaces (i.e. desquamative gingivitis) as being susceptible 
to the common plaque-related gingivitis too. 
 Systemic therapy has been proposed in literature to control 
exacerbations of OLP [23], but topical application has been consid-
ered as the most suitable and effective as well as the easiest to prac-
tice and, hence, the first line of treatment [24].  
 In general, topical administration consists in a direct application 
on the lesions of natural substances/drugs or in use of a device (e.g. 
excimer laser), it has been found almost to be successful in oral soft 
tissue diseases, thanks to the easy accessibility of the mouth. How-
ever, it is important to underline that until today only few topical 
formulations are specific for oral mucosa diseases, whilst most of 
them are adopted from dermatology with all the limitations associ-
ated to this; let us consider that the structural and functional fea-
tures of the oral mucosa, above all in terms of permeability, are  
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Fig. (1). Bullous OLP: before and after treatment with topical clobetasol 
proprionate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Desquamative gingivitis hystologically confirmed as OLP: before 
and after treatment with topical clobetasol proprionate. 
 
different to those of the skin. The presence of salivary flow that 
constantly wets the oral surfaces, in association with the swallow-
ing, chewing and phonation, acts washing away most of the drug 
from the site of application resulting in a short retention time of the 
dosage forms and consequently in a low therapeutic efficacy. In 
addition, the presence of salivary enzymes could degrade the drug 
molecules and the bioadhesive polymers from the dosage forms. 
However, the oral mucosal surface is coated by a thin layer of mu-
cus, that on one hand limits functions of permeability barrier, but on 
the other hand is one of the most important structures for the bioad-
hesion of the drug delivery systems [25]. To resolve all the limita-
tions linked to the oral environment, the research today concen-
trates on the development of new bioadhesive formulations of the 
dosage forms to allow an efficient oral local drug delivery. In order 
to allow a longer residence time of the drug on the application site 
and consequently to a better bioavailability and therapeutic effi-
cacy, the dosage forms should have in their formulation: a) muco-
adhesive polymers (in order to provide an intimate and prolonged 
contact with the absorption site); b) chemical penetration enhancers 
(in order to improve drug permeation across oral mucosa or drug 
penetration into the deepest layers of the epithelium); and c) enzy-
matic inhibitors, in order to eventually protect drugs from the en-
zymatic degradation. 
 As stated above, oral local drug delivery consists in a more 
efficient drug-delivery approach than the systemic delivery one for 
the treatment of oral mucosal conditions. The reasons to prefer a 
local drug delivery to treat the oral soft tissue diseases are linked to 
their high frequency, their chronic status (requiring chronic treat-
ment regimens) and above all to their excellent response to topical 
drugs.  
 Topical drug application avoids the need for ingestion and sys-
temic distribution of drugs, provides a more targeted delivery as 
smaller amounts of drug can be easily targeted to the not healthy 
site, thereby reducing side effects.  
 The main disadvantages of local oral drug delivery are related 
to small surface area of the oral mucosa, to the limited exposure 
times [26] and to the bad taste sensation (especially during long-
term treatments). Hence, local drug delivery should be considered a 
delivery route appropriate for drugs exhibiting high therapeutic 
potency as relatively small quantities of drugs can be delivered. 
 Mucoadhesive systems for the oral local drug delivery include: 
adhesive tablets, adhesive patches, adhesive films or pellicles, ad-
hesive semi-solid systems (gels, ointments), adhesive liquid sys-
tems (sprays, mouthwahses). 
 As regards the application in the field of OLP, mucoadhesive 
tablets, [11, 27-29], bioadhesive gels [30], lipid microspheres [31] 
and oral rinses [32] are the most studied mucoadhesive dosage form 
for oral topical drug delivery.  
 When a mucosal condition as OLP has an immunologic patho-
genesis, treatment with topical immunomodulators may be appro-
priate [27, 33-35]. The most prescribed topical drugs (Table 2) are 
corticosteroids for their anti inflammatory and immunosuppressant 
properties [36], with the use of two to three times a day, while fur-
ther systemic dosage forms are reserved only in some particular and 
refractory cases.  
 In a recent review [32], Thongprasom et colleagues assessed the 
effectiveness and safety of any form of therapy for symptomatic 
OLP, concluding that although topical steroids are considered to be 
first line treatment, but there is no evidence that one steroid is any 
more successful than another. Furthermore, they continue to vali-
date aloe vera as able to reduce the pain of OLP and improve the 
clinical signs of disease compared to placebo as well as cy-
closporine, while there is no evidence that other calcineurin inhibi-
tors reduce pain compared to either steroids or placebo. From the 
28 trials included in this systematic review, the extensive collection 
of interventions compared means there is insufficient evidence to 
support the effectiveness of any treatment as being superior. 
 Besides, recently it has been considered as useful topical cal-
cineurin inhibitors in OLP management as second-line treatment 
[33, 37].  
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 The aim of this paper is to review the available literature re-
garding any topical substances or applications to treat OLP, this in 
the view to help any specialist involved in managing this treatment 
and the respective pros and cons.  
Steroids 
 A variety of synthetic glucocorticoids has been projected for 
therapeutic use and each substance is characterized by gluco-
corticoid potency, duration of effect, and overlapping mineralo-
corticoid potency varies. Hydrocortisone (pharmaceutical prepa-
rations of cortisol) is the standard of comparison for glucocorticoid 
potency. Topical steroids are categorized in potency class according 
to relative anti-inflammatory activity, but the action could differ 
significantly depending upon the vehicle, the site of application, the 
disease or the patient. Oral potency may be less than parenteral 
potency because significant amounts (up to 50% in some cases) 
may not be absorbed from the intestine. Topical corticosteroids as 
triamcinolone acetonide 0.1%, fluocinolone acetonide 0.1% and 
fluocinonide 0.05% and clobetasol proprionate 0.05% are princi-
pally investigated and used for treatment of OLP. 
 In particular, clobetasol -17-propionate, a synthetic corticoster-
oid analogue of prednisolone, has met a great consensus; it is the 
most potent (highest potency class) topical steroid [38], with a 
complete decrease rate of OLP lesions from 47% to 75% [39]. 
 The drug is very effective as a vasoconstrictor, an anti-
inflammatory and antiproliferative agent; moreover when topically 
administered, it allows good management of diseases reducing sys-
temic side-effects for the patient. Prolonged contact with the oral 
mucosa should be avoided, since this may damage mucosal barriers 
and induce local immunosuppression, predisposing to oropharyn-
geal candidosis, one of the most common side-effects of topical 
corticosteroid therapy [40, 41]. For this reason, a concomitant ad-
ministration of topical antifungal drugs is often proposed. 
 Clobetasol propionate ointment (0.05%) is demonstrated to be 
more successful than triamcinolone acetonide and fluocinonide in 
clinical trials [42]. 
 Steroid mouthwashes (betametasone 500g dissolved in 20 mL 
of water or clobetasol in acqueous solution) are used in cases of 
widespread OLP, even though systemic effects could be secondary.  
 Sometimes, topical application could be inadequate and not 
effective due to the aqueous solution, hence some adhesive denture 
pastes [16] and ointments [30] have been proposed over the last 
decade. 
 The extent of absorption by a topical corticosteroid, including 
clobetasol propionate, is determined by the vehicle or others fac-
tors, related to the applied dosage form as well as the integrity of 
the buccal mucosal barrier. Campisi et al. [26] evaluated the effi-
cacy and compliance of a new delivery approach, loaded lipid mi-
crospheres, in an observer-blinded randomized clinical trial (RCT) 
of patients with OLP. Furthermore, Cilurzo et al [43] recently re-
ported the excellent adhesion of tablets containing 24 g –
clobetasol 3 times/day and confirmed the effectiveness in absence 
of systemic side effects. 
Table 1. Algorithm of management of OLP lesions (modified from Carrozzo M et al, 2009 and Lodi G et al, 2005) 
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 In a randomized cross over study, Hegarty et al [44] investi-
gated the acceptability and efficacy of topical fluticasone propion-
ate spray (50 g two dose unit sprays) and betamethasone sodium 
phosphate mouthrinse (500 g 4 times daily), both administered for 
a period of 6 weeks, on the signs and symptoms of 44 OLP patients, 
evaluating also benefits of patient quality of life. Both substances 
caused a statistically significant reduction in painful symptoms, and 
improvement in quality of life. There was no significant difference 
between the two corticosteroids in their efficacy in reducing painful 
symptoms (measured by the VAS) or in their effect on patient qual-
ity of life. Fluticasone propionate was statistically significantly 
better than betamethasone sodium phosphate in reducing lesion 
surface area. Both are effective in the short-term clinical manage-
ment of symptomatic OLP and fluticasone propionate is more suit-
able to patients than betamethasone sodium phosphate since it is in 
the spray form. 
 The efficacy of mometasone furoate microemulsion upon the 
symptoms and signs of OLP has been determined by a pilot phase II 
clinical trial [45]. In 49 subjects with erosive-ulcerative OLP, of 
0.1% mometasone furoate microemulsion mouthwash was pre-
scribed for three times a day over 30 days and pain, erythema and 
ulceration were assessed after 15 and 30 days of treatment. Mome-
tasone caused a statistically significant reduction in pain, in clinical 
aspect and no one of these patients showed severe adverse effects, 
demonstrating that it is a safe and effective therapy in the treatment 
of symptomatic erosive-ulcerative OLP. 
 Efficacy of a triamcinolone acetonide, in two forms, has been 
evaluated in 20 OLP patients instructed to use a mouthwash (n = 
11) or a commercially available triamcinolone acetonide paste (n = 
9). The mouthwash was well accepted by patients and ten out of 11 
patients treated for four weeks reported a positive response, and a 
complete response in signs and symptoms occurred in 4 and 5 of 11 
patients, respectively. No significant difference in clinical im-
provement was observed between two formulations in OLP [46]. 
 Another study [47] aimed to evaluate the efficiency and safety 
of triamcinolone acetonide by means injection in ulcerative OLP. 
Forty-five patients received 0.5 ml triamcinolone acetonide (40 
mg/ml) on lesions, after registration of visual analogue scale score 
and lesion areas at the time of injection and 1-week interval. After 2 
weeks, if the treated ulceration reduced < 81% in size, a second 
injection was given. Patients revealed rapid relief of signs and 
symptoms, while the control group showed minimal decrease, since 
intralesional injection of triamcinolone acetonide in ulcerative OLP 
is effective and safe to achieve lesion and pain regression. 
 Of note, prolonged employ of these drugs could determine 
tachyphylaxis: for this reason, initially it is useful to prescribe a 
very potent steroid (e.g. clobetasol) and then, for maintenance ther-
apy, a moderately potent steroid (e.g. triamcinolone) [48]. 
Calcineurin Inhibitors (Cyclosporina, Pimecrolimus, Tac-
rolimus) 
 They are microbially derived immunosuppressive agents bind 
to cytoplasmic receptors of T lymphocytes, determining complexes 
that inhibit calcineurin and leading to suppression of cytokines 
transcription and production. Calcineurin-inhibitors as cy-
closporine, tacrolimus, and pimecrolimus are of clinical benefit in 
oral immunomediated disease regimens. 
Firstly, topical application of cyclosporine was reported by Eisen 
[10, 49-52] who compared it with placebo, showing an enhance-
Table 2. Topical Treatments Proposed for OLP 
STEROIDS ANTIOXIDANTS OTHERS 
Triamcinolone acetonide 0.1% Retinoids Tetracyclineh 
Fluocinolone acetonide 0.1%  Tretinoina Sirolimus or rapamycinh 
Fluocinonide 0.05%a  Tarazotenea,i Hyaluronic acida,j 
Clobetasol propionatea,b  Isotretinoina Aloe veraa,k 
Fluticasone propionatec  Fenretinide Herbal medicines 
Betamethasone sodium phosphatec  Laser Therapy 
Mometasone furoated BIOLOGICS  LLLTl 
 Alefacept  Laser evaporationl 
CALCINEURIN INHIBITORS Efalizumab Photo Dynamic Therapyl  
Cyclosporinea,e Basilixima Extracorporeal photochemotherapyl 
Pimecrolimusa,f TNF- inhibitors  
Tacrolimusa,g Etanercept  
 Infliximab  
 Adalimumab  
 BCG-PSNa  
 Rituximab  
DESCRIPTION OF EFFICACY -aEfficacy confirmed by controlled-clinical trial; bmore efficacy than triamcinolone acetonide and fluocinonide and few side effects; c effective in 
the short-term clinical management; dpilot phase II clinical trial; ereviews suggest a non well clinical response; f a medium/long term follow up has been reported only from cases 
report studies, more researches and comparisons with other treatments are needed; g represent a likely alternative to topical steroids; honly few reports published; itransient burning 
sensation and dysgeusia as side effects; jefficacy for up to 4 h after administration, it could be used as maintenance therapy of OLP, alternating it with topical corticosteroids; keffi-
cacy on pain and burning sensation score, size and clinical characteristics of the lesions; lonly case series  
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ment of clinical signs (e.g. erythema, erosion) and soreness in a 
small group received cyclospsorine. Different studies (RCT, open 
trails, case reports) [53] have investigated the efficacy of cy-
closporine (prepared in a concentration of 15-100 mg/ml and ad-
ministrated 3 times/day for 6-8 weeks) in OLP management. In a 
clinico-experimental evaluation [54] the Authors assessed topical 
therapy of OLP with cyclosporine by bioadhesive gel formula (car-
bosymethylcellulose) supporting adhesion for 2 hours. The regimen 
was carried out on 6 patients for 8 weeks with a low dose (48 
mg/day) and showed remarkable results with a reduction ranging 
from 50 to 80% of oral lesions. On the contrary, other studies con-
sidered this result as not consistent, reporting a scarce help of cy-
closporine application. Sieg et al. [55] have conducted a RCT de-
termining that triamcinolone acetonide was better than cyclosporine 
in symptomatic OLP as well as Voute’s group in an open trial [56]. 
Also with respect to the use of sulodexid (via intramuscular- 600 
units before and by oral 250 units 2 times/day) during an open trial, 
cyclosporine rinse (100 mg/ml 3 times/day for 3 minutes) has 
shown less rapid healing [11]. In a RCT [57], though clinically it 
has been observed a better improvement in patients undergone to 
steroid respect to cyclosporine group, the enhancement of pain is 
similar when patients applied steroids or cyclosporine. In a case 
series study [13, 58] it has been evaluated cyclosporine in patients 
with desquamative gingivitis: six patients used cyclosporine solu-
tion (100 mg/ml) to rinse one time for 5 minutes every day. In five 
patients it has been observed a complete resolution of gingival 
soreness within 2-4 weeks, while there were persistent lesions on 
dorsum of the tongue and gingival; hence, no patient had total heal-
ing of involved areas. Reviews on different topical and systemic 
regimens [59] have confirmed a not well response after administra-
tion of cyclosporine, with a lack of strong evidence of efficacy. 
 Pimecrolimus 1% cream has been tested in 20 patients for 2 
months showing a statistically high significant improvement of 
lesions (87%) and a significant decrease of VAS (93%) and con-
cluding that it appears to be a promising alternative treatment for 
OLP [18]. In a prospective randomized double-blind vehicle-
controlled study[60] it has been confirmed that pimecrolimus cream 
(1%) could be helpful in patients with erosive OLP when it is ap-
plied twice daily for one month, determining healing (lesions and 
symptoms) in seven of ten patients versus an improvement only in 
two patients of the other group. When pimecrolimus was applied 
for further 30 days, a resolution has been observed in three subjects 
who do not respond to pimecrolimus the first month. Moreover, in a 
RCT pimecrolimus 1% cream, when applied for 2 months, did not 
confirm a better effectiveness of OLP symptoms and signs respect 
to topical triamcinolone acetonide [61] but both groups showed 
enhancement of all variables with no significant differences. Passe-
ron et al [62] observed an improvement of erosive OLP when pa-
tients are treated with pimecrolimus 1% cream during the first 
phase but also had relapsed after cessation of therapy. Furthermore, 
blood levels of pimecrolimus remained above threshold with a 
mean value of 2.84 ng/ml. Only a transient burning sense is re-
ported by some patients. In a 6-week randomized, double-blind, 
vehicle-controlled phase followed by a 6-week open-label phase, 21 
patients with erosive OLP were randomized and treated with 
moreover pimecrolimus 1% cream or vehicle cream to evaluate the 
effectiveness and safety of pimecrolimus. Pimecrolimus 1% cream 
was superior to vehicle in reducing pain, erythema, decreasing ero-
sion size, and improving overall severity of disease when compared 
with vehicle treatment [19, 63]. To our knowledge, a medium/long 
term follow up has been reported only from cases report studies 
[64-66] with a confirmation of pimecrolimus as an efficient poten-
tial treatment for OLP, although more research is needed to evalu-
ate the efficacy of pimecrolimus and to study potential , as well as 
to establish its true role in comparison with other treatments for 
OLP. 
 Regarding tacrolimus, its efficacy has been evaluated by several 
open-label prospective studies [15, 16], randomized trials [67, 68], 
retrospective studies [69, 70], case series [71, 72] and case reports 
[70]. Topical tacrolimus, in two concentrations 0,03% and 0,1%, is 
competent to obtain relief of pain, even if the first one does not 
warrant a complete healing, whereas its cessation determines recur-
rences within 1 or 2 weeks [13]. Since minimal side effects are 
reported [15] (<25% of treated individuals), the use of tacrolimus 
could be suggested as a first line treatment in steroid- recalcitrant 
lesions, in susceptible patients for candidiasis and for other immu-
nosuppressive-adverse effects. Tacrolimus could be considered as 
notably superior to topical corticosteroids for the treatment of OLP, 
but available data should be warily assessed since dissimilar prepa-
rations and concentrations of tacrolimus are used. 
 In a RCT Corrocher et colleagues [73] treated 32 OLP patients 
with tacrolimus (0,1%) or clobetasol (0,05%) ointment (four 
times/day for four weeks). Generally, symptoms ameliorated in 
both group after treatments, thought scores (e.g. pain, burning, le-
sions size) were lower in tacrolimus group compared to clobetasol 
one, even if in a first phase nine subjects felt a worsening that has 
been resolved after a week. In either group no side effects have 
been described. 
 In another study [65], it was compared the efficacy of topical 
tacrolimus ointment with triamcinolone acetonide ointment in pa-
tients with oral lichen planus. In a group of 20 patients, they were 
treated with topical tacrolimus 0.1% ointment 4 times daily, and in 
another group of 20, they applied triamcinolone acetonide 0.1% in 
ointment 4 times daily; both groups used ointments for 6 weeks. In 
the first group, 6 patients revealed healing, 12 improvement and 2 
showed no improvement. In the second group, 2 patients healed, 7 
improved and 11 remained without improvement. Temporary burn-
ing or stinging at the site of application was the most common re-
ported side-effect in both groups. Unluckily, in 13 of the first group 
and in 7 of the second group, who had initially shown an improve-
ment or healed, oral lesions reappeared after 3-9 weeks of ending of 
treatment. A better initial therapeutic response of topical tacrolimus 
0.1% ointment was determined respect to use of triamcinolone ace-
tonide 0.1% ointment.  
 In a prospective study [74] 10 patients affected by refractory 
OLP used tacrolimus mouthwash (0,01 mg/100ml in distilled wa-
ter): seven of eight subjects that completed the study, improved 
clinically and in symptoms in six months. After the end of therapy, 
OLP relapsed and they were treated with steroids to which they 
responded well. Authors concluded that tacrolimus rinse in low 
concentration could relieve the symptoms effectively. 
 In an open clinical trial [13] it has been appraised the clinical 
efficacy and safety profile of tacrolimus powder in orabase 0.1% in 
7 patients with OLP and 3 lichenoid lesions. 
 Before initiating tacrolimus regimen, all patients received a 1 
week treatment of fluconazole, the most symptomatic site were 
treated, three times a day for two weeks; after two weeks, amelio-
rated of signs and symptoms was achieved in most patients. 
Authors concluded that tacrolimus powder in orabase 0.1% ap-
peared to have a relatively safe profile, and represents a likely al-
ternative to topical steroids in the treatment of OLP and lichenoid 
lesions, especially in those at risk for oral candidosis. 
 There is no objective evidence supporting an increased risk of 
oral malignancy in association with use of topical tacrolimus and 
pimecrolimus [75, 76], although some authors [77-85] reported two 
cases of carcinoma in OLP patient treated with topical tacrolimus 
for long term. 
Tetracycline 
 They are widely prescribed for infections supported by a variety 
of gram positive bacterial microorganisms and by others as myco-
plasms, chlamydiae, rickettsiae. The topical efficacy of tetracy-
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clines in recurrent aphthouts stomatitis and white sponge nevus has 
been assessed and published [86].  
 Regarding use of tetracyclines in OLP, in the literature there is 
a report of significant amelioration in a patient after one week of 
rinses of tetracycline solution (0,25%) for 2-4 min, three times per 
day, the resolution of erosive OLP with healing has been observed 
after six weeks, although white lesions continued [87].  
Sirolimus 
 Also known as rapamycin, it is an immunosuppressant drug 
used to prevent rejection in organ transplantation. Sirolimus was 
originally developed as an antifungal agent but this use was 
abandoned when it was discovered to have potent immuno-
suppressive and antiproliferative properties. It has been studied for 
OLP topical management in a small study [88] rapamycin solution 
(1mg/ml) was applied for three months twice a day in erosive OLP 
lesions in seven patients; although a patients gave up the study 
since a burning sensation for the application of sirolimus, after 3 
months four patients had total resolution and two a partial 
remission.  
Antioxidants 
 The oxidative stress plays an important role in the pathophysi-
ology of OLP increasing the release of cytokines and free radicals 
(ROS) by damaged keratinocytes [89]. 
 Thirthy years ago, Gunther [90] described the use of retinoids 
(tretinoin) in the treatment of OLP: the retinoids as physiological 
metabolites of retinol (vitamin A) have been used as anti-
keratinizing factor to regulate the synthesis of keratins through a 
specific action on the sulfhydryl radicals. These metabolites have 
antioxidant and anti-inflammatory properties and are involved in 
many physiological processes, particularly with regard to cellular 
differentiation [91].  
 The efficacy of topical isotretinoin gel 0.1% has been also as-
sessed by Piattelli et al. in a placebo-controlled study. Ten patients 
with OLP were treated for 4 months with 0.1% isotretinoin gel and 
another ten patients with placebo. After treatment with isotretinoin, 
patients showed a complete or partial response, whereas, in the 
control group, no improvement of lesions has been observed. At the 
3-year follow-up complete healing was achieved in 9 of the 15 pa-
tients, whereas in 6 cases there was a recurrence of the lesion. His-
tologically and immunohistochemical analysis with antibodies 
against Bcl-2 (protein implicated in apoptosis regulator process) 
and Ki-67 (nuclear protein associated with ribosomal RNA tran-
scription) showed a reduction of apoptotic bodies accompanied by 
an increase of Bcl-2 and Ki- 67. The researchers concluded that the 
increase of these proteins could have contributed to the healing 
process. Differently from the systemic formulations, the topical 
dosage regimen would allow an impressive effect resulting in a 
higher concentration of the substance directly to the surface with 
few adverse effects [92]. 
 In a double- blind placebo-controlled study, Petruzzi et al. 
treated 12 patients with an adhesive gel of tarazotene (0,1 %) ap-
plied twice a day on the lesional mucosal tissue for eight weeks. 
The authors concluded that topical gel of tarazotene seems to be 
more effective in test group versus the control one. Transient burn-
ing sensation and dysgeusia represented the minimal side effects 
observed [29]. 
Hyaluronic Acid 
 Hyaluronic acid (HA) is a glycosaminoglycan (GAG), with the 
major role in tissue healing: it is implicated in a range of activities 
including activation and moderation of the inflammatory responses, 
promoting cell proliferation, migration and angiogenesis, promoting 
re-epithelization, via proliferation of basal keratinocytes and reduc-
ing collagen disposition and scarring [29]. 
 In a blinded parallel-group randomized clinical trial [93] the 
efficacy of a local HA preparation (0.2%) was evaluated in 120 
patients with erosive OLP. All subject were instructed to apply on 
the lesions 4-5 times daily for a total of 28 days. In addition, 5 and 
60 minutes after each application the patients recorded scores of 
oral function and soreness on a clinical diary. In patients treated 
with HA, a decrease of pain for up to 4 hours post application and a 
reduction of ulcerative areas were registered. Furthermore, no sig-
nificant differences between the two groups in relationship to oral 
function was found. The authors suggest that regular and very fre-
quent applications of HA could be taken into account in order to 
obtain a more lasting action [94]. 
 Cirillo’s data [95, 96] demonstrate that keratinocytes represent 
a previously underestimated target for HA action in wound healing 
and serve as a peripheral neuroendocrine system that may play a 
role in nociception. HA preparations induce transcriptional changes 
in keratinocytes and stimulate wound closure. Furthermore, the 
addition of synthetic aminoacids to sodium hyaluronate (Ami-
nogam®) induces a distinct transcriptional profile and potentially 
promotes analgesia via secretion of endorphin in keratinocytes. The 
same compounds, in a spray dosage form, have been successfully 
used for the treatment of radio/chemotherapy-induced oral mucosi-
tis, with a significantly and positive impact on pain and lesion ame-
lioration [97]. Although no controlled randomized clinical trial 
exists, at this regard HA being a natural compound without side 
effects could be used as maintenance therapy of OLP.  
Aloe Vera  
 A double blind, placebo-controlled trial was designed by 
Choonhakarn  et al. [98] in fifty-four patients assigned in two 
groups of 27 OLP subjects. The patients were instructed for appli-
cation of Aloe vera (AV) twice daily for a total of 8 weeks. Im-
provement without complete healing of ulcerative lesions was ob-
served in 22 of patients treated with AV, while one of 27 patients 
who received placebo had a similar response. Poor feedback was 
achieved in 2 AV subjects compared with 13 placebo patients. An 
absence of improvement in one AV patient and in 13 placebo pa-
tients have been registered. Disappearance of lesions was observed 
in 2 patients treated with AV, while none of the placebo group had 
a complete remission. Only in seventeen patients treated with AV, 
alleviation of the clinical symptoms were observed versus two pla-
cebo patients. Burning pain completely disappeared in nine patients 
treated with AV (33%) and in one treated with placebo [99]. 
 Also Salazar-Sánchez et al [100] have confirmed that the topi-
cal application of AV could improve the total quality of life score in 
patients with OLP. 
 In a randomized double-blinded clinical trial, Mansourian et al. 
[101] aimed to compare the therapeutic effects of aloe vera (AV) 
mouthwash with triamcinolone acetonide 0.1% (TA) on OLP. They 
observed that baseline characteristics, including pain and burning 
sensation score, size and clinical characteristics of the lesions ac-
cording to Thongprasom index, were reduced in the 2 treatment 
groups, concluding that AV mouthwash is an effective substitute 
for TA in the treatment of OLP. 
Herbal Medicines  
 Herbology is one of the most important treatment modalities for 
oral diseases utilized by Traditional Chinese Medicine (TCM) 
[101]. Each herbal prescription is a cocktail of several herbs. Even 
though TCM has studied for 2000 years for the treatment of differ-
ent diseases, it is not completely understood and accepted by the 
clinicians outside China, especially since it is not based on an evi-
dence-based system, but experience-based. The Chinese pharmaco-
poeia lists over 6000 medicinal substances and their properties. 
Among these substances around 600 herbs are commonly used 
today. Among these Liuwei Dihuang, Tripterygium wilfordii, Com-
posite Taixian tablet, and Zengshengping are commonly used in the 
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treatment of a wide spectrum of autoimmune and inflammatory 
diseases, demonstrating efficacy in treating oral diseases including 
oral lichen planus, but sometimes lacking standard criteria of post-
treatment assessment and laboratory evidence. Zheng [102] re-
ported that in 1997 Xian investigated the concomitant administra-
tion of Liuwei Dihuang and retinoic acid cream in 43 patients with 
OLP with more effective results than retinoic acid cream alone, 
particularly for treating the patients with a history of OLP less than 
3 years. 
Laser Therapy 
 Laser consists of an active medium hit by emitted energy from 
an external source (pumping system), that absorbs photons and 
transfers electrons from one energy level to a higher (inversion 
population). The active medium is a structure called "optical reso-
nator" that allows photons emitted spontaneously to trigger the 
mechanism of stimulation and to generate, after a threshold, the 
laser beam. The emitted photons will be characterized by fre-
quency, amplitude and wavelength.  
 In relation to the active medium, there are several types of la-
sers used in oral medicine: diode laser, excimer laser, low-level 
laser therapy (LLLT), CO2 laser.  
 Aghahosseini et al. [103] experienced the treatment of 26 le-
sions in 13 patients, evaluating the signs, symptoms and size of the 
lesions. A diode laser (632 nm, 120 J/cm
2
) for 2 minutes was used. 
The analysed data showed a significant reduction in the size of 
lesions and a decrease of pain in 16 lesions.  
 Köllner et al. [104] used the excimer laser 308 nm-UVB for the 
intraoral treatment in eight patients with OLP. During treatment, the 
lesions were exposed to a variable number of application (from 9 to 
32) and energy density per minute (from 75 to 175 mJ/cm
2
). The 
results showed improvement in six patients, in particular complete 
remission was achieved in two cases, while one patient showed 
recurrence of the lesions after 4 weeks.  
 In an single center observational study, Trehan et al. [105] as-
sessed the efficacy of excimer laser therapy (initial fluencies 100 
mJ/ cm
2
, subsequently once a week 400 mJ/ cm
2
) in management of 
nine patients affected by OLP in a follow up ranged from 2 to 17 
months. Low-dose treatment with the excimer 308-nm laser can be 
very effective in treating symptomatic and especially erosive OLP, 
an otherwise notoriously difficult-to-control disease. 
 On the other hand, not satisfactory results have been reported 
by Passeron [106] in four patients presenting erosive OLP. The 
authors evaluated the use of 308 nm excimer laser twice a week for 
12 sessions. The lowest dose was 50 mJ/cm
2
, increased by 50 
mJ/cm
2
 every two sessions up to 200 mJ/ cm
2
. Only one patient 
showed positive results.  
 The low-level laser therapy (LLLT) was described by Cafaro et 
al, using 904 nm 4 J/cm
2
 per minute (10 kHz, 50% duty cycle) with 
a distance of approximately 2 mm from the oral mucosa. All 13 
patients reported a reduction in clinical signs as well as in pain 
[107]. A comparative pilot study of LLLT versus topical corticos-
teroids in the treatment of erosive-atrophic OLP demonstrated that 
LLLT is as effective as topical corticosteroid therapy without any 
adverse effects and it may be considered as an alternative treatment 
for erosive-atrophic OLP in the future [108]. 
 The CO2 laser was another investigated laser system in oral 
medicine; Van der Hem et al. [109] exposed 39 superficial OLP 
lesions to CO2 laser evaporation (1,5-2.0 Joule/mm
2
). During a 
follow-up period of 1–18 years (mean 8 years) 24 lesions showed 
no more signs of oral dysfunction (pain, burning sensation). Fifteen 
lesions showed clinical recurrence, six of these caused pain after 
complete epithelialization. After retreatment with CO2 laser evapo-
ration of these six lesions, no pain complaint was observed. In all 
patients, complete epithelialization after treatment completion and 
retreatment was observed in 3 weeks. 
Photo Dynamic Therapy and Extracorporeal photochemother-
apy  
 Photodynamic therapy (PDT) is a treatment that uses a sub-
stance, called photosensitizer or photosensitizing agent, and a par-
ticular type of light, such as a laser. PDT could be considered a safe 
alternative treatment in patients who do not respond to standard 
therapy or with contraindications to steroids. Methylene Blue (MB) 
is an optimal photosensitizer for PDT, it has a strong absorption at 
wavelengths longer than 620 nm, and it may be a preferred choice 
for superficial lesions in skin and oral cavity. 
 Aghahosseini [110] investigated the effectiveness of photody-
namic therapy with MB in two patients with oral lichen planus. The 
patients were instructed to gargle a 5% methylene blue solution in 
water for 5 minutes (0.05 gr per 100 cc). After ten minutes the le-
sions were treated with light source (diode laser 632 nm, 100 
J/cm
2
). They were followed up on sessions 3, 7, 15 days and 1 to 9 
months after PDT. In two lesions, an improvement was achieved, 
and in two other lesions a complete remission was observed.  
 Extracorporeal photochemotherapy (ECP) or photopheresis, a 
type of PDT, is an emerging treatment in which a centrifugal 
apheresis machine is used to separate the patient’s blood cells. The 
removed cell are treated with a photosensitizing compound (8-
methoxypsoralen), that was intercalated into DNA of treated cells 
making them more susceptible to apoptosis when exposed to ultra-
violet A light. The cells are then re-infused to the patient. 
 ECP has been investigated by Kunte et al. [111] to assess their 
safety in 4 patients with erosive oral lichen planus reporting an 
improvement of symptoms and lesions in all subjects after seven to 
nine therapy cycles. 
 Twenty patients suffered from erosive lichen were enrolled in a 
study conducted by Guyot. ECP were performed twice weekly for 3 
weeks while the following sessions were planned according to 
clinical improvement. The researchers monitored counts of periph-
eral blood CD4 +, CD8 T- lymphocyte and subsets every 3 months. 
In all patients, clinical improvements were observed [112]. 
 In another study ECP has been used successfully in the treat-
ment of two patients with oral erosive and cortico-resistant lichen 
planus [113]. 
Biologics 
 The introduction of biologic therapies is a new challenge for the 
treatment of various immune-mediated disorder, in particular for 
unmanageable OLP. Biologics are intended by recombinant bio-
technology to head off every step in the pathogenesis of immunoin-
flammatory diseases, representing a more effective and targeted 
approach. Structurally, biologics include receptor fusion proteins, 
monoclonal antibodies, and recombinant cytokines. Functionally, 
biologics can be divided into T-cell or cytokine modulators. As 
biotechnology agents directly and⁄or indirectly target T cells, ale-
facept, efalizumab, basilixima, TNF- inhibitors (i.e. etanercept, 
infliximab, adalimumab), polysaccharide nucleic acid fraction of 
bacillus Calmette–Guerin (BCG-PSN), and rituximab are used for 
treatments of OLP [114].  
 Xiong et al, [115] in a randomized control trial, have used im-
munologic active materials to regulate T cells (CD4 and CD8 cells) 
and subtypes of helper T cells (Th1 and Th2): topical injection (0.5 
ml) of Polysaccharide nucleic acid fraction of bacillus Calmette-
Guerin (BCG-PSN) into the connective tissue below the erosive 
lesion from adjacent normal mucosa was compared with the intrale-
sional injection (10 mg) of Triamcinolone Acetonide (TA). The 
injection was administered weekly for 2 weeks. This study involved 
56 patients (31 treated and 25 control) all affected with severe ero-
sive OLP unresponsive to conventional therapies. There were no 
statistical differences between the two groups in the reduction of 
clinical signs (erosion), alleviation of pain and burning sensation, 
recurrence rate and occurrence of adverse reactions. These findings 
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show that topical BCG-PSN are as effective as topical TA and 
might be useful as a therapeutic alternative for erosive OLP.  
DISCUSSION AND CONCLUSIONS  
 The management of OLP is very difficult due to its chronic 
nature that requires a long-term treatment [116], and World Health 
Organisation considers OLP as “a generalized state associated with 
a significant increased risk of cancer”. The cause of increased oral 
cancer risk in OLP patients is unknown but the highest rate of trans-
formation regards especially the erosive and erythematic forms 
[36], that must be always treated. 
 In general, according to EAOM guidelines [117], OLP treat-
ment is necessary only when it is symptomatic and regarding the 
therapeutic options, oral local drug delivery consists in a more effi-
cient approach than systemic administration for the treatment of 
oral mucosal conditions. The reasons to prefer a local drug delivery 
to treat the oral soft tissue diseases are linked to their high fre-
quency, their chronic status (requiring chronic treatment regimens) 
and above all to their excellent response to topical drugs.  
 There are several studies on molecule different from gluco-
corticosteroids, but not sufficient or statistically adequate to justify 
their evidence based use in OLP; a further criticism is the scarcity 
in literature of standardized evaluation parameters during the OLP 
management (e.g. lesions size, VAS scale). 
 Specifically, to assess the effectiveness and safety of any form 
of therapy for symptomatic OLP, Thongprasom and colleagues 
[118, 119] reviewed all randomised controlled clinical trials (RCTs) 
of OLP therapy with the Cochrane collaboration in which treatment 
with a placebo or between treatments or no intervention have been 
compared, concluding that there is no evidence that a specific 
treatment is more effective than another.  
 To date, the application of immunosuppressive drugs, such as 
glucocorticoid, appears to be the safest and most effective topical 
treatment available, even if there is much dispute about their long-
term efficacy and benefits, and there is a wide scenario with several 
different molecules proposed, at least of auxiliary benefit.  
 It seems extremely interesting and novel the research investigat-
ing on endogenous steroidal system in keratinocytes [118, 119]. 
 In fact, the bioavailability of circulating and/or endogenous 
hydrocortisone (cortisol) in epidermal cells is a key determinant in 
inflammatory disease. However, it is unknown whether epidermal 
cells can regulate tissue cortisol and whether they are capable of 
producing endogenous glucocorticoids [117, 118]. A further key 
observation is that keratinocytes responded to stimulation with 
ACTH by a significant increase in the de novo synthesis of cortisol. 
The same authors have recently reported that epidermal keratino-
cytes can be considered a new non-adrenal glucocorticoid- system 
endogenously implicated in regulation of cortisol: data showed that 
oral fibroblasts and keratinocytes were able to activate cortisone 
into the active form cortisol, and confirmed the capacity of synthe-
sizing cortisol de novo following stimulation with ACTH; particu-
larly, when the isoenzyme11b-Hydroxysteroid dehydrogenase 
(HSD)1/2 is present, it controls cortisol deactivation. Supplemen-
tary close examinations to control bioavailability of circulating 
cortisol in epidermal cells are awaited, and well-designed random-
ized controlled trials should be carried out to establish the accurate 
effectiveness of topical administration for the treatment of immu-
nologically mediated oral mucosal disease as OLP. 
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